BIIB vs. CNC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BIIB and CNC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BIIB | CNC |
|---|---|---|
| Company Name | Biogen Inc. | Centene Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 24.51 billion USD | 18.40 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | September 17, 1991 | December 13, 2001 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BIIB and CNC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BIIB | CNC |
|---|---|---|
| 5-Day Price Return | 7.23% | 6.22% |
| 13-Week Price Return | 20.89% | 27.69% |
| 26-Week Price Return | 36.04% | -38.31% |
| 52-Week Price Return | 1.06% | -37.32% |
| Month-to-Date Return | 8.61% | 2.86% |
| Year-to-Date Return | 9.57% | -39.95% |
| 10-Day Avg. Volume | 1.95M | 10.00M |
| 3-Month Avg. Volume | 1.62M | 14.43M |
| 3-Month Volatility | 33.63% | 53.24% |
| Beta | 0.10 | 0.47 |
Profitability
Return on Equity (TTM)
BIIB
9.26%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
BIIB’s Return on Equity of 9.26% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
CNC
-20.61%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
CNC has a negative Return on Equity of -20.61%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
BIIB
15.99%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
BIIB’s Net Profit Margin of 15.99% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
CNC
-2.85%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
CNC has a negative Net Profit Margin of -2.85%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
BIIB
21.91%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
An Operating Profit Margin of 21.91% places BIIB in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
CNC
-3.07%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
CNC has a negative Operating Profit Margin of -3.07%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | BIIB | CNC |
|---|---|---|
| Return on Equity (TTM) | 9.26% | -20.61% |
| Return on Assets (TTM) | 5.67% | -6.26% |
| Net Profit Margin (TTM) | 15.99% | -2.85% |
| Operating Profit Margin (TTM) | 21.91% | -3.07% |
| Gross Profit Margin (TTM) | 75.24% | 8.14% |
Financial Strength
Current Ratio (MRQ)
BIIB
2.72
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
BIIB’s Current Ratio of 2.72 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
CNC
1.08
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
CNC’s Current Ratio of 1.08 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
BIIB
0.35
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
BIIB’s Debt-to-Equity Ratio of 0.35 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
CNC
0.84
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
CNC’s Debt-to-Equity Ratio of 0.84 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BIIB
4.35
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
BIIB’s Interest Coverage Ratio of 4.35 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
CNC
7.06
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
CNC’s Interest Coverage Ratio of 7.06 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | BIIB | CNC |
|---|---|---|
| Current Ratio (MRQ) | 2.72 | 1.08 |
| Quick Ratio (MRQ) | 2.05 | 1.08 |
| Debt-to-Equity Ratio (MRQ) | 0.35 | 0.84 |
| Interest Coverage Ratio (TTM) | 4.35 | 7.06 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
CNC
0.00%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
CNC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
CNC
0.00%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
CNC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BIIB | CNC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BIIB
15.20
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
In the lower quartile for the Biotechnology industry, BIIB’s P/E Ratio of 15.20 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
CNC
--
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
P/E Ratio data for CNC is currently unavailable.
Price-to-Sales Ratio (TTM)
BIIB
2.43
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
In the lower quartile for the Biotechnology industry, BIIB’s P/S Ratio of 2.43 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
CNC
0.10
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
In the lower quartile for the Health Care Providers & Services industry, CNC’s P/S Ratio of 0.10 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
BIIB
1.13
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
BIIB’s P/B Ratio of 1.13 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
CNC
0.84
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
CNC’s P/B Ratio of 0.84 is in the lower quartile for the Health Care Providers & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | BIIB | CNC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 15.20 | -- |
| Price-to-Sales Ratio (TTM) | 2.43 | 0.10 |
| Price-to-Book Ratio (MRQ) | 1.13 | 0.84 |
| Price-to-Free Cash Flow Ratio (TTM) | 10.81 | 4.47 |